Stocks Health care KZIA
NASDAQ · Health careKazia Therapeutics Ltd (KZIA)
Kazia Therapeutics Ltd reported revenue of A$42K in fiscal 2025, down 98.2% from a year earlier. It posted a net loss of A$20.7M. At June 30, 2025 it held A$4.3M in cash.
Key facts about Kazia Therapeutics Ltd
- Net worth
- Kazia Therapeutics Ltd has a market value (market cap) of $84.7M at the latest share price, and shareholders' equity of -A$8.3M on its balance sheet at June 30, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was A$42K (-98.2% year on year), with a net loss of A$20.7M.
- Cash flow
- In fiscal 2025 operations used A$13.3M of cash.
What Kazia Therapeutics Ltd does
Kazia Therapeutics Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KZIA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | A$42K | -A$20.7M | -A$0.04 | n/a |
| 2024 | A$2.3M | -A$26.8M | -A$0.10 | n/a |
| 2023 | A$0 | -A$20.5M | -A$0.11 | n/a |
| 2022 | A$0 | -A$25M | -A$0.19 | n/a |
| 2021 | A$15.2M | -A$8.4M | -A$0.07 | n/a |
| 2020 | n/a | -A$12.5M | -A$0.17 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Kazia Therapeutics Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 2, 2026Form NT 20-F filing NT 20-F
- October 2, 2026Passive stake changed SCHEDULE 13G/A
- September 22, 2026
- September 18, 2026
- September 1, 2026
- August 31, 2026
- August 31, 2026
- August 28, 2026
- August 27, 2026
- August 19, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Kazia Therapeutics Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns KZIA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Chernett Jorey13G, passive | 19.6% | August 19, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 36 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Boxer Capital Management, LLC | 560,000 | new |
| Flputnam Investment Management Co | 414,958 | +272,489 |
| Bleichroeder LP | 400,000 | 0 |
| Ikarian Capital, LLC | 396,201 | new |
| Dauntless Investment Group, LLC | 354,208 | +274,376 |
| Stonepine Capital Management, LLC | 345,179 | 0 |
| Point72 Asset Management, L.P. | 200,300 | +300 |
| Ensign Peak Advisors, Inc | 110,778 | new |
| Millennium Management LLC | 101,376 | new |
| UBS Group AG | 81,090 | +67,156 |
| J. Goldman & Co LP | 68,491 | new |
| ADAR1 Capital Management, LLC | 61,550 | new |
| Jane Street Group, LLC | 57,140 | new |
| Barclays PLC | 56,999 | +33,000 |
| Susquehanna International Group, Llp | 50,616 | new |
| Cooperman Leon G | 50,000 | new |
| Westside Investment Management, Inc. | 47,585 | -2,840 |
| Morgan Stanley | 46,606 | +45,606 |
| Marshall Wace, Llp | 44,231 | new |
| XTX Topco Ltd | 31,186 | new |
Insiders
Questions about KZIA
What does Kazia Therapeutics Ltd do?
Kazia Therapeutics Ltd is a company in the Health care sector, listed on NASDAQ as KZIA. Its shares trade on NASDAQ under the ticker KZIA.
What is Kazia Therapeutics Ltd's net worth?
Kazia Therapeutics Ltd has a market value (market cap) of $84.7M at the latest share price, and shareholders' equity of -A$8.3M on its balance sheet at June 30, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Kazia Therapeutics Ltd profitable?
No. In fiscal 2025 it reported a net loss of A$20.7M on revenue of A$42K.
How much revenue does Kazia Therapeutics Ltd make?
In fiscal 2025 Kazia Therapeutics Ltd reported revenue of A$42K. That is 98.2% less than a year earlier.
When did Kazia Therapeutics Ltd last report?
Its newest filing of any kind is the form NT 20-F filing from November 2, 2026.
Similar companies
Compare KZIA with
Follow KZIA
Get an email when Kazia Therapeutics Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Kazia Therapeutics Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.